insitro, founded in 2018 in South San Francisco by Daphne Koller, combines machine learning with human genetics and cell data to find drug targets and medicines. It raised a $400 million Series C in March 2021.
At a glance
| Price from | Custom |
| Best for | Pharma partners working on metabolic and neurological disease |
From insitro's own website.
What stands out
- Large pharma partnership with milestones
- Founded by machine learning pioneer Daphne Koller
Worth knowing
- No drug in the clinic yet
- Last large equity round was some time ago
How it ranks
insitro is ranked 5th of 10 in Best AI Drug Discovery Startups (Lister Score 92.0).
#5 in Best AI Drug Discovery Startups · Lister Score 92.0
AstraZeneca signed a 2026 collaboration with insitro that pays $40 million upfront, with up to about $1.46 billion in milestones..
| Rank | Best AI Drug Discovery Startups | Score |
|---|---|---|
| 1 | Isomorphic Labs | 97.1 |
| 2 | Xaira Therapeutics | 95.8 |
| 3 | Chai Discovery | 94.6 |
| 4 | Enveda | 93.3 |
| 5 | insitro | 92.0 |
| 6 | Formation Bio | 90.7 |
| 7 | Genesis Molecular AI | 89.4 |
| 8 | BigHat Biosciences | 88.1 |
| 9 | Terray Therapeutics | 86.7 |
| 10 | Cradle | 85.3 |
Frequently asked questions
How does insitro rank on Lister?
insitro is ranked 5th of 10 in Best AI Drug Discovery Startups (Lister Score 92.0).
Appears in
Add this badge to your site
If you work at insitro, paste this code into your website to show where it ranks on Lister. The badge links to the ranking and updates within a day when the rank changes.